Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
18.75
Nov 16 • 3:59 PM ET Dollar change-0.35 Percentage change(-1.83%)
Aftermarket Close
18.75
Aftermarket • 5:54 PM ET Dollar change0.00 Percentage change(0.00%)
Nov 13, 10:15 AMGH Research reports positive initial FDA feedback on planned pivotal TRD program
Index
-
Market Cap
1.29B
Enterprise Value
924.76M
Income
-62.27M
Sales
0.00M
Book/sh
5.24
Cash/sh
5.28
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
73
IPO
Jun 25, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.58
P/C
3.55
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
28.70
Current Ratio
28.70
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.99
EPS next Y
-1.54
EPS next Q
-0.27
EPS this Y
-24.88%
EPS next Y
-55.69%
EPS next 5Y
-29.91%
EPS past 3/5Y
-22.35% -162.03%
Sales past 3/5Y
- -
EPS Y/Y TTM
-33.76%
Sales Y/Y TTM
-
EPS Q/Q
-52.04%
Sales Q/Q
-
Insider Own
25.83%
Insider Trans
0.00%
Inst Own
72.56%
Inst Trans
8.87%
ROA
-18.16%
ROE
-18.79%
ROIC
-17.32%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-3.62%
SMA50
-15.19%
SMA200
-13.62%
Trades
Shs Outstand
68.64M
Shs Float
50.91M
52W High
31.44 -40.36%
52W Low
12.04 55.73%
Volatility
6.40% 6.62%
ATR (14)
1.26
RSI (14)
41.01
Beta
1.33
Rel Volume
2.31
Avg Volume
279.06K
Volume
643,964
Perf Week
-2.65%
Perf Month
3.31%
Perf Quarter
-36.94%
Perf Half Y
-13.51%
Perf YTD
47.64%
Perf Year
33.93%
Perf 3Y
156.15%
Perf 5Y
-18.55%
Perf 10Y
-
Prev Close
19.10
Price
18.75
Change %
-1.83%
Consensus
Strong Buy
Avg. Price Target
$40.50
Implied Upside
+116.0%
Analysts7incl. previous ratings
Rating Distribution7 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 27, 2026Initiated
WFC logoWWells Fargo
Overweight$44+134.7%
Oct 13, 2025Initiated
NNeedham
Buy$19+1.3%
Jun 04, 2025Resumed
CCantor Fitzgerald
Overweight$25+33.3%
Mar 13, 2025Initiated
GGuggenheim
Buy$32+70.7%
Mar 07, 2025Initiated
RY logoRRBC Capital Mkts
Outperform$31+65.3%
Feb 13, 2025Initiated
CCantor Fitzgerald
Overweight$14-25.3%
Aug 16, 2022Initiated
HH.C. Wainwright
Buy$45+140.0%
Jun 16, 2022Initiated
RROTH Capital
Buy$66+252.0%
GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schonharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
Co-Founder & Non-Executive Chairman of the BoardMr. Florian Schonharting M.Sc. (Econ)
M.Sc.Dr. Velichka Valcheva M.D.
Co-Founder & MD of IrelandMr. Magnus Halle
Vice President of FinanceMs. Julie Ryan F.C.A.
Chief Operating OfficerMr. Aaron Cameron M.B.A.